This type of HUS is termed "atypical", as it is unrelated to an infection with enterohaemorrhagic E. coli (EHEC Eculizumab was recently very successfully used to block complement in the treatment of paroxysmal nocturnal haemoglobinuria (PNH), in which red blood cells are lysed by complement due to an inherited lack of inhibitors on their cell surface.